"the potential of a Co Development Partnership." I agree with that concept Eire. I may be a bit "tunnel vision" on the future of the Company but I still think that AVR is planning to be around for a long time. With the personnel on the Board and the Advisory Body and the technical staff employed it is a solid organisation and the tone of the interview seemed to lead towards going it alone -
"you don’t need a thousand reps, you don’t need massive infrastructure. We’re set up here in Minneapolis with a facility that can actually manufacture and does manufacture from clinical trials of course, can take us through our first two years on our forecast of the commercial usage as well. So, it’s a concentrated market, there’s not huge numbers of centres that you have to cover and really, only 20 to 30 to 40 centres really do most of the volume. So, getting into the market, even though we’re up against companies of course that are larger than we are, is not as challenging as some folks might imagine it to be if they don’t really understand how the space operates"
AVR Price at posting:
$21.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)